Chimerix to Present at Two Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 12 /PRNewswire/ -- Chimerix, Inc., a
biopharmaceutical company advancing orally-available antiviral therapeutics to
address life-threatening diseases, announced today that Kenneth I. Moch, Chief
Operating Officer, will present a corporate overview at two upcoming investor
conferences. Mr. Moch will discuss the company's technology assets and
pipeline, including CMX001, a broad-spectrum antiviral being developed for the
treatment of BK virus and cytomegalovirus in immunocompromised transplant
patients and as a biodefense countermeasure in the event of a smallpox
release.

Mr. Moch will speak at the Lazard Capital Markets 6th Annual Healthcare
Conference on Wednesday, November 18, 2009 at 9:30 a.m. ET and at the Piper
Jaffray 21st Annual Health Care Conference on Tuesday, December 1, 2009 at
9:50 a.m. ET. Both meetings are being held in New York City.

About Chimerix
Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening
diseases. Led by a world-class antiviral drug development team, Chimerix is
advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human
immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial
virus (RSV) and influenza. The company's lead compound, CMX001, is currently
in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV,
potentially deadly infections among immunocompromised patients. CMX001 is
also being evaluated for use as a biodefense countermeasure in the event of a
smallpox release. Chimerix has received financing from leading venture
capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures,
Frazier Healthcare Ventures and Asset Management Company, in addition to U.S.
Government grants. Additional information about Chimerix and its antiviral
drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.

Kenneth I. Moch, Chief Operating Officer of Chimerix, Inc., +1-919-313-2961;
or Karen L. Bergman or Susan M. Pietropaolo, both of BCC Partners,
+1-650-575-1509, or +1-201-923-2049, for Chimerix, Inc.